1. The metabolism of an intravenous pulse dose of double-isotope-labelled cholecalciferol has been studied in control subjects with widely differing states of vitamin D nutrition and in patients with primary disorders of parathyroid function.
Introduction
The metabolism of vitamin D 3 (cholecalciferol) to its hydroxylated derivatives has been shown to occur in man along pathways similar to those established in experimental animals. 25-Hydroxycholecalciferol [25-(OH)D 3 ] (1 ) has been isolated from human plasma (Holick, DeLuca & Avioli, 1972) ; the active metabolite, 1,25-dihydroxycholecalciferol [1, , has been detected in serum (Mawer, Backhouse, Lumb & Stanbury, 1971a) , as has 24, Mawer, 1974) . The kinetics of the production and decay of 25-(OH)D 3 
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in man, after a pulse of isotopically labelled cholecalciferol, have been studied in detail, and it has been shown that the state of vitamin D nutrition is the most important single factor affecting the conversion of a test dose of radioactive cholecalciferol into labelled 25-(OH)D 3 (Mawer, Lumb, Schaefer & Stanbury, 1971b; Mawer, Backhouse, Holman, Lumb & Stanbury, 1972) . Study of the formation of 1,25-(OH)zD 3 in man is much more difficult. Only a very small fraction of an administered dose of labelled cholecalciferol appears subsequently in the blood in the form of 1,25-(OH)2D3 (Mawer, Backhouse, Taylor, Lumb & Stanbury, 1973) and this can be measured only when the subject is vitamin D-deficient (Mawer, 1974) . The quantitative state of vitamin D nutrition required to prevent the formation of labelled 1,25-(OH)zD3 is not known, nor are the mechanisms by which the nutritional state determines this effect. In studies of the formation of 1,25-(OH)zD3 in disease, this particular problem has been circumvented by the deliberate selection for study of patients with a state of vitamin D nutrition matching that of control subjects shown to be capable ofproducing detectable amounts of labelled 1,25-(OH)2D 3 (Mawer et aI., 1973; Mawer, 1974) . This approach has permitted the detection of gross qualitative abnormalities, such as the impaired biosynthesis of 1,25-(OH)zD3 in advanced renal failure , but it cannot be applied directly to study the control of 25-(OH)D 3 metabolism.
The purpose of the present studies was to attempt to delineate the factors which control the further metabolism of 25-(OH)D 3 in man, using doubleisotope-labelled cholecalciferol as tracer and the concentration of 25-(OH)D 3 in serum as the best available quantitative measure of the nutritional state. Effects of extremes of parathyroid activity were observed in patients with primary hyperparathyroidism or hypoparathyroidism, who were selected for investigation on the basis of their relatively low state of vitamin D nutrition, as in previous similar studies from this laboratory. Controls for these particular studies were provided by parallel observations on subjects with comparable levels of serum 25-(OH)D 3 , who for the purposes of the investigation could be considered 'normal'. Observations were extended to include otherwise normal subjects with widely ranging states of vitamin D nutrition, from a degree of deficiency sufficient to cause osteomalacia. to a state of surfeit produced by exposure to sunshine or the deliberate administration of cholecalciferol. Since this extreme spectrum of vitamin D nutrition was accompanied by changes in the serum concentrations. of calcium, inorganic orthophosphate and immunoreactive parathyroid hormone, it was possible to relate the pattern of 25-(OH)D 3 metabolism to these variables as well as to the serum 25-(OH)D 3 •
Methods

Subjects studied
Studies with radioactive cholecalciferol were undertaken in twenty individuals with a wide range of nutritional state with respect to vitamin D (group 1, Table I ). These included patients with overt clinical signs of vitamin D deficiency or with reasons for the potential development of vitamin D deficiency (cases 1-9), and volunteers, healthy individuals or patients with indifferent diseases, considered clinically to be replete with the vitamin (cases 10-20). Of the latter, two (cases 11 and 15) had recently been exposed to sunshine on holiday and three (cases 18-20) had previously received 5·2 jlmol (2 mg) of cholecalciferol orally for the purpose of the investigation (see Table 1 ). It is considered that these twenty subjects differ significantly only in respect of their 'vitamin D status'; for convenience in description and for comparison with patients with primary disorders of parathyroid function, they are referred to as the 'control' group.
A second group (group 2, Table 2 ) comprised nine patients with surgically proved primary hyperparathyroidism and two with hypoparathyroidism complicating thyroid surgery. Trephine biopsies (2 mm) were obtained from the iliac crest, after tetracycline labelling in vivo, in the patients with primary hyperparathyroidism: all showed binding of the label at the sites of bone formation (Dr J. Ball) and thus, on this basis, none had a primary defect of mineralization.
Studies with radioactive cholecalciferol were undertaken in two other groups of subjects, at a time before we were able to trace the formation of labelled 1,25-(OH)2D 3 • The state of vitamin D nutrition in these individuals was assessed by the biologically assayed anti-ricketic activity of serum and not by the serum 25-(OH)D 3 • Group 3 comprised sixteen otherwise healthy 'control' subjects, with as wide a range of vitamin D nutrition as in (1) Bone biopsy showed evidence of osteomalacia with varying degrees of osteitis fibrosa. Other cases designated as osteomalacic had overt clinical and radiographic features of the disease.
(2) Cases 18-20 received 5·2 pmol (2 mg) of cholecalciferol orally, 1 week before administration of the dose of radioactive cholecalciferol. (Mawer et al., 1971a, b) . Data from groups 3 and 4 appear only in Fig. 1 ; they were not used in any of the statistical analyses. The nature of the investigation was fully explained to all subjects who consented voluntarily to take part.
Experimental design
An initial blood sample was obtained for the measurement in serum of immunoreactive parathyroid hormone, total 25-hydroxycalciferols and total anti-ricketic activity. Each subject then received an intravenous injection (Mawer, Lumb & Stanbury, 1969) Venous blood samples were obtained 24 hand 48 h after the injection. In a proportion of subjects, additional blood samples were obtained at intervals up to 6-10 days.
• The concentrations of labelled cholecalciferol and its metabolites were measured by counting the radioactivity in chromatographically separated fractions of serum extracts. Lipid extracts of serum were prepared as described previously (Mawer & Backhouse, 1969) .
Cholecalciferol and its hydroxylated metabolites were separated by column chromatography on Sephadex LH20 (pharmacia, Uppsala). The twostage method, which is a modification of that of Holick & DeLuca (1971) , has been described elsewhere (Taylor, Mawer & Reeve, 1973) . The first column was eluted with chloroform-hexane (13:7, v/v) and the first 90 ml of eluate was collected, concentrated under nitrogen and re-chromatographed on the second column. This was eluted with chloroform-hexane (1: 1, v/v) to separate cholecalciferol and 25-(OH)D 3: the dihydroxylated metabolites of cholecalciferol were eluted from the first column by larger volumes of chloroformhexane (13:7, v/v).
A peak of radioactivity corresponding to 24,25-(OH) ZD 3 was eluted at 130-140 ml; a second peak at about 250 ml contained 1,25-(OH)zD 3 together with other material believed to be 25,26-(OHhD3 (Haussler & Rasmussen, 1972) . The proportion of 1,25-(OH) zD 3 in this latter peak was calculated from measurement of the 3H/14C ratio (Mawer et al., 1971a) . During the renal synthesis of 1,25-(OHhD 3 , tritium is selectively lost from the 10c position, resulting in a decrease in the 3H/14C ratio (Lawson, Wilson & Kodicek, 1969a, b) .
Separated chromatographic fractions were dissolved in scintillator (Mawer et al., 1971b) and monitored for 3H and 14Cradioactivity in a NuclearChicago automatic liquid-scintillation counter. A dual-isotope computer program enabled both isotopes to be counted without cross-contamination.
Radioimmunoassay ofparathyroid hormone
Determinations were made on separated serum by a method modified from Arnaud, Tsao & Littledike (1971) . Two different antisera (367 and 211/32), prepared in guinea-pigs against the bovine hormone, were always used in triplicate assays.
Purified bovine hormone (biological activity in the thyro-parathyroidectomized rat, 2800-3000 (Aurbach, 1959) and subsequent gel filtration (Rasmussen & Craig, 1962; Aurbach & Potts, 1964) . Labelled hormone was prepared from this material by the method of Hunter & Greenwood (1962) and purified according to Schopman, Hackeng & Lequin (1970) . The product had a specific radioactivity of 1·0-1·5 mCi/lO Jig of hormone. The purified bovine hormone was initially used as standard. Subsequently, the pooled media from cultures of human parathyroid adenomata were assayed at numerous dilutions in human hypoparathyroid serum, given a bovine equivalent value and used for preparing standards in subsequent assays.
Reagents in the assay consisted of: 0·2 ml of unknown serum or dilution of test serum in hypoparathyroid serum; 0·1 ml of antiserum solution; 0·6 ml of Herbert's buffer. Antiserum solution consisted of 1[15000 antiserum and 1/100 normal guinea-pig serum in Herbert's buffer with Trasylol 100 i.u.[ml (Bayer Pharmaceuticals). Control solution was the same with antiserum omitted. After vortex mixing the samples were incubated for 4 days at 4°C: 0·1 ml of labelled hormone (3000 d.p.m.) was added and the samples were remixed and incubated for a further 4 days at 4°C. The free and bound fractions were separated by Dextrancoated charcoal (Herbert, Lau, Gottlieb & Bleicher, 1965) .
Both antiserum 367 and 211[32 detect immunoreactive hormone in 85% of normal individuals, with a range of concentration of 0-0·8 ng[ml (bovine equivalents). In a direct comparison of sera from twenty-six normal individuals, the mean values were 0-42 ng[ml (so 0'31) and 0·35 ng[ml (so 0·3) with antiserum 367 and 211/32 respectively. Preliminary observations with this assay used to assess static and kinetic secretory states in secondary hyperparathyroidism have been published (Lumb & Stanbury, 1974) .
Estimation of total anti-ricketic activity in serum
Total anti-ricketic activity in serum was assayed by the line test as previously described (Lumb, Mawer & Stanbury, 1971) . The measured biological activity may include contributions from ergocalciferol, cholecalciferol and both 25-hydroxylated derivatives. The concentration of 1,25-(OHhD J in serum (q.v.) is too low to make a significant contribution.
Protein-binding assay for 25-hydroxycalciferols
The concentration of total 25-hydroxycalciferols in serum was determined by competitive proteinbinding assay, a method modified from Haddad & Chyu (1971) being used. The method does not distinguish between 25-hydroxyergocalciferol and 25-hydroxycholecalciferol; for convenience and simplicity, results of assays are expressed as 25-
The lipids were extracted from 2 ml of serum by homogenization with 15 ml of diethyl ether-ethanol (9: 1, v[v) . The two phases were allowed to separate at room temperature, the ether layer was removed and the remaining lower phase washed twice with 10 ml of ether. The total ethereal extracts were combined and evaporated to dryness under nitrogen. The residue, dissolved in 1·5 ml of chloroformhexane (1: 1, v/v), was applied to a column (50 em x 0·5 em) packed with 3·5 g of Sephadex LH20 equilibrated with the same solvent mixture, which was also used for elution. The first 11 ml was discarded; the next 10 ml, which contained the 25-(OH)D J , was collected and evaporated to dryness in a stream of nitrogen. Recovery (about 85%) from the extraction and chromatographic procedures was estimated by incorporating an internal standard (700 d.p.m.) of 25-[26,27-JH]hydroxycholecalciferol (6'9 Ci[mmol; The Radiochemical Centre). The binding protein was prepared from the kidneys of vitamin Ddeficient rats (Haddad & Chyu, 1971) .
The dried 25-(OH)D J fraction from the column was dissolved in 1 ml of ethanol and 50 Jil samples, equivalent to 0·1 ml of serum, were pipetted into tubes for assay by the method of Haddad & Chyu (1971) .
The limit of detection in this assay was 0·625 pmol per assay tube. With sera assaying at less than 7·5 nmol/l the determination was repeated with the equivalent of 0·2 ml of serum. All assays were performed in triplicate. Variation within assay was 10% and between assays 8%.
The normal range established in a group of seventeen healthy laboratory personnel was 22,5-150 nmol/I (mean 72 nmol/I; so 38) in samples obtained between July and November; 15-70 nmol/I (mean 40·5 nmol[l; so 15) in sera collected in April and May. In patients with osteomalacia due to vitamin D deficiency, the corresponding values were 5,25-15,25 (mean 11·0 nmol/I; so 7'0; n = 8) for June to November; 4'0-21'0 (mean 9·95 nmol/I; so 4'7; n = 12) for December to May. Other apparently healthy individuals, receiving less solar exposure than the laboratory staff, had concentrations of serum 25-(OH)D3 between 15 and 22·5 nmol/I (e.g, see Table 1 ). It is to be emphasized that the presence of osteomalacia cannot be equated with particular absolute levels of serum 25-(0H)D 3 (Stanbury, Torkington, Lumb, Adams, de Silva & Taylor, 1975) .
Derivation of molar concentrations of cholecalciferol metabolites in the serum
The specific radioactivity of 25-(OH)D 3 in the serum, 24 h after injection of labelled cholecalciferol, was calculated as: 24,25-(OHhD 3 at 48 h after injection of the radioactive cholecalciferol. These are the times at which maximum concentrations of the respective metabolites are normally observed in man .
Effects of vitamin D status on the serum concentration ofradioactive 25-(OH)D 3
The percentage of serum radioactivity in the form of unchanged cholecalciferol, 24 h after injection of the labelled pulse, was directly related to the assayed total anti-ricketic activity in the serum (groups 3 and 4; Fig. 1 ). All subjects with assayed activity exceeding the equivalent of 78 pmol of cholecalciferol/ml of serum had received supplementary vitamin D and previous observations The basic assumption made is that this corresponds approximately to the specific radioactivity of the labelled dihydroxylated derivatives measured in the serum at 48 h. It is further assumed that the size of the extracellular pool of 25-(0H)D3 is not changing significantly in this period; this is justified by previous observations . On this basis, the molar concentrations of 1,25-(OHhD3 and 24,25-(0H) 2D 3 were calculated from their respective radioactivities (see Table 4 ).
Statistical methods
Standard procedures were as described by Snedecor (1946) and Bailey (1959) and non-parametric methods by Siegel (1956) . Standard deviation is designated throughout as so: the symbol ± is used only with SEM values. FlO. 2. Relationship between the assayed serum concentration of 25-(OH)D 3 and the fraction of serum radioactivity in the form of cholecalciferol, 24 h after injection of labelled cholecalciferol. ., Control subjects of Group 1. Patients: primary hyperparathyroidism before (L,,) and after (.l) parathyroidectomy; 0, hypoparathyroidism. Arrows denote results from two additional cases of primary hyperparathyroidism not included in Table 2 . The same symbols are used in subsequent diagrams. 25 nmolfl 25-(OH)D 3 == 10 ng/ml.
Results
Clinical and biochemicaldata, together with measurements of vitamin D metabolites, are shown in Table 1 for control subjects and in Table 2 for patients with primary disorders of parathyroid function.
For comparative and statistical purposes, data are given for serum-concentrations of labelled 25- Fig. 2) .
The regression of the serum concentration of labelled 25-(OH)D 3 on the concentration of nonradioactive 25-(OH)D 3 in the twenty control subjects is shown in Fig. 3 . The data from the patients with primary hyperparathyroidism lie within the 95% confidence limits of this regression . In subsequent description, the serum concentration of non-radioactive 25-(OH)D 3 (serum 25-(OH)D 3 ) is used as the index of vitamin D status.
Effects of vitamin D status on the formation of labelled dihydroxylated derivatives
The relationship between the serum 25-(OH)D 3 and the serum concentration of radioactive 1,25-(OH),D 3 at 48 h is shown in Fig. 4 inversely related to the serum 25-(OH)D 3 (r = -0·68; P < 0·01 ; Fig. 4 ).
In the primary hyperparathyroidism group, all patients produced labelled 1,25-(OHhD3 but there was no correlation between serum 25-(OH)D 3 and serum radioactive 1,25-(OHhD 3 (r = 0'1). Neither patient with hypoparathyroidism produced labelled 1,25-(OHhD3 • Among the fourteen control subjects with serum 25-(OH)D 3";25 nmol/l, labelled 24,25-(OHhD 3 was detectable in the serum at 48 h in only two individuals, with serum 25-(OH)D3 of 17·5 and 22·5 nmol/l respectively; above these values, the serum 25-(OH)D 3 and serum 24,25-(OH) 2D 3 were directly correlated (Fig. 5 ), but the relationship was not significant. However, in some vitamin D-deficient subjects, labelled 24,25-(OH) 2D 3 became detectable in serum samples obtained 6-10 days after injection of the tracer; this occurred only after the concentration of labelled 1,25-(OH) 2D 3 had started to diminish.
All patients with primary hyperparathyroidism had detectable amounts of labelled 24,25-(OHhD3 in the serum at 48 h (Fig. 5) , and the concentration of this metabolite was directly but insignificantly correlated with the serum 25-(OH)D 3 as in the control subjects (r = 0'52; P>O·I; n = 9).
Thus in control subjects labelled 24,25-(OH)D 3 The nine patients with primary hyperparathyroidism were matched with an equal number of control subjects. Significance of differences between the two groups was assessed by the two-tailed Mann-Whitney U-test (Siegel,1956 (1) Only two or three subjects in the control group produced measurable amounts of 24,25-(OHhD 3 and therefore no so value is given. was the predominant dihydroxylated metabolite produced when body vitamin D was adequate (serum 25-(OH)D 3 > 25 nmol/l) and labelled 1,25-(OHhD 3 was produced in states of relative vitamin D deficiency. Formation of these two metabolites appeared to be on a reciprocal basis in that significant amounts of both were not found in anyone subject (Table 1 ). In the primary hyperparathyroidism group this relationship was not evident and all patients produced significant amounts of both 1,25-(OHhD3 and 24,25-(OHhD 3 ( (Table 2 ) was much narrower than in the twenty controls (Table 1) . In Table 3 , data from the primary hyperparathyroidism group are compared with selected controls, who were matched for vitamin D status on the basis of the 25-(OH)D 3 assay. The groups were indistinguishable in their conversion of cholecalciferol into 25-(OH)D 3, and the concentrations of 1,25-(OH)2D3 were not significantly different; the concentration of 24,25-(OH)2D3 was much higher in the primary hyperparathyroidism group (P < 0'02, Table 3 ). The sum of the concentrations of these two labelled metabolites in the last-named group was approximately 2'7 times that in the matched controls (Table 3 ). The mean creatinine clearance (Ce-) of 63 ml/min (SD 25'5) in the group implies that renal function, and thus probably also renal mass, was reduced in several of these patients. This could imply an even greater production of labelled dihydroxylated metabolites, per unit mass of renal tissue, in the hyperparathyroidism group than in their control subjects. There was, however, no significant correlation between Cc-and the serum labelled 1,25-(OHhD3 in the hyperparathyroidism group (r = 0'22).
The metabolism of labelled cholecalciferol was observed in three patients after removal of a parathyroid adenoma (cases 28, 29 and 30, Table 2 ). The formation of labelled 25-(OH)D 3 (Fig. 3) , 1,25-(OHhD3 and 24,25-(OH) 2D3 (Table 2) was indistinguishable from that of control subjects with comparable vitamin D status.
Relation of vitamin D metabolites in the serum to the serum concentrations of calcium and phosphorus: control subjects
There were significant direct relationships between the serum 25-(OH)D 3 and the serum calcium, phosphorus and [Cal x [P] product (Fig. 6) .
The relationships between the serum calcium and the concentrations of labelled dihydroxylated derivatives at 48 h are shown in Fig. 7 . Serum 1,25-(OH)D 3 was inversely related to the serum calcium (P <0,001). No labelled 24,25-(OHhD 3 was detect 
Interrelationships of the variables correlating with the formation of labelled 1,25-(OH) 2D 3 : control subjects
In the thirteen subjects who produced measurable amounts of labelled 1,25-(OH)2D 3, its serum concentration (Y, 10 2 x % of doserl) was related to the serum calcium (Xl> mmolJl) and the serum 25-(OH)D 3 (X2, nmol/l) by the partial regression equation: y = 34,2-12,28 (±4'24)xI-0'156 (±0'068)X2
Relation of serum immunoreactive parathyroid hormone to the formation ofl,25-(OH) 2D 3 in control subjects
In the fifteen control subjects for whom measurements of immunoreactive parathyroid hormone were available (Table 2) able when the serum calcium was less than '2'3 mmol/l (9'2 mg/l00 ml); above this value the two variables were positively but insignificantly correlated (r = 0'37; P>O·I; n = 7; Fig 7) . Labelled 1,25-(OH)2D3 was formed in association with serum concentrations of PI between 0·58 and 1-1 mmol/l (1,8 and 3·4 mg/l00 ml) (Table I) , and there was no significant correlation between these two variables. No labelled 24,25-(OHhD3 was detectable in subjects with serum PI <0·97 mmol/l: FIG. 7 . Relationships, in control subjects (e) and patients with primary hyperparathyroidism (6) , between the serum calcium and the serum concentrations (at 48 h) of (a) 
Metabolism of cholecalciferol in hypoparathyroidism
The formation of labelled 25-(OH)D 3 was appropriate to the vitamin D status of the two patients studied ( Measurements of serum immunoreactive parathyroid hormone from eight patients with primary hyperparathyroidism showed no correlation with the serum concentration of labelled 1,25-(OHhD3 (Fig. 9) . There was also no relationship between the serum hormone and the serum concentration of labelled 24,25-(OHhD3 in this group of patients. 
Relations of serum concentrations of labelled 1,25-(OH) 2D3 and 24,25-(OH)2D3 to serum calcium, phosphorus and immunoreactive parathyroid hormone in patients with primary hyperparathyroidism
In this group of patients there was no significant correlation between the serum concentration of labelled 1,25-(OHhD3 and the serum calcium, PI or [Cal x [PI] product. The concentration of labelled 24,25-(OHhD 3 correlated positively, almost reaching significance, with the serum calcium (r = 0·61; 0·05<P<0·1; Fig. 7 ) and inversely but Both partial regression coefficients were significantly different from zero (Xl, P < 0·01; X2, P < 0'05). This implies that an increase of either independent variable (Xl, X2) was associated with a decrease of serum labelled 1,25-(OH)2D3 when the influence of the other was eliminated; or a decrease of either the serum 25-(OH)D 3 or serum calcium might independently increase the formation of 1,25-(OHhD 3 • Because assays of immunoreactive parathyroid hormone were not available in all subjects (Table I) , partial regression analysis could not be extended to the third variable (X3), the serum hormone. The relationship between serum labelled 1,25-(OHhD 3 and the serum hormone (y = 2'35 + 3·58 (±0'57)x3) was, however, of a high order of significance (P < 0'001). There are thus no mathematical grounds for attaching primary significance in control of the formation of 1,25-(OHhD3 to any of the three variables considered. (I) Sum of the concentrations of unlabelled 25-(OH)D 3 measured by protein-binding assay and the 25-(OH)D 3 derived from the injected pulse of labelled cholecalciferol.
(2) A, concentration before injection of tracer dose; B, concentration 48 h after the injection.
high for the prevailing serum calcium but probably appropriate to the serum phosphorus.
Derived molar concentrations of metabolites of cholecalciferol in the serum
The method of derivation of the molar concentrations of 1,25-(OH)2D 3 and 24,25-(OH)2D3 in the serum is demonstrated for representative subjects in Table 4 .
The mean increment in the concentration of 25-(OH)D 3 in the serum 24 h after the injected pulse of cholecalciferol, was not significantly different in the primary hyperparathyroidism group (4'35 nmol/I; so 1'0) and in the twenty control subjects (3,67 nmol/I; so 1'69).
The range of estimated concentrations of 1,25-(OH)2D3 in the serum of the thirteen control subjects producing labelled metabolite was 45-132 pmol/I (mean 90 pmol/I; so 25); the mean value increased to 122 pmol/I (so 25) after injection of labelled cholecalciferol. In the nine patients with primary hyperparathyroidism, the corresponding mean values of 148 pmol/I (so 66) and 177 pmol/l (so 74) were both significantly higher (P~0'01). This difference is adequately explained by the different nutritional state in the two groups; the mean serum 25-(OH)D3 was 21·1 nmol/l (so 6'0) in the hyperparathyroidism group and 14·5 nmoljl (so 6'0) in the thirteen control subjects, among whom were several patients with clinical vitamin D deficiency ( Table 1) .
The estimated mean serum concentration of 24,25-(OHhD3 was 3·4 nmoljl (so 3'48) in the eight control subjects producing labelled metabolite and 173 pmol/l (so 99) in the nine patients with primary hyperparathyroidism. This difference was related to the much higher values of serum 25-(OH)D3 in these eight control subjects (65,6 nmol/I; so 30'4).
Discussion
The present investigation confirms the previous observation in man that the formation of labelled 1,25-(OH)2D3 from an administered pulse of radioactive cholecalciferol is detectable only in subjects relatively deficient of vitamin D. Among individual control subjects, no labelled 1,25-(OHhD 3 was detected when the serum 25-(OH)D 3 exceeded 25 nmol/I (Table 1); and, by regression analysis, the mean limiting value of serum 25-(OH)D 3 was approximately 37·5 nmol/I (Fig. 4) . Below this limiting concentration there was a significant inverse relationship between the serum concentration of non-radioactive 25-(OH)D 3 and of labelled 1,25-(OH) 2D3. In the fourteen subjects of group 1 (Table 1) with serum 25-(OH)D 3~25 nmolrl there was only a small variation in the serum concentration of labelled 25-(OH)D 3 at 24 h (mean 6·91% dosejl ; so 1-17). There was no correlation between these values and the serum concentrations of labelled 1,25-(OHhD 3 at 48 h (r = 0'13); but the latter values were significantly correlated with the specific radioactivity of serum 25-(OH)D3 at 24 h (r = 0'71; P < 0,01). Thus the principal determinant of the concentration of labelled 1,25-(OH)2D 3 in the serum was the concentration of serum 25-(OH)D 3 at the time of injection of the tracer. This relationship (Fig. 4) might imply that the formation of labelled 1,25-(OH) 2D3 was regulated in some way by the prevailing state of vitamin D nutrition; but it could result from dilution of labelled 25-(OH)D 3 into pre-existing body pools of 25-(OH)D 3, the radioactive enrichment of the 1,25-(OH)2D 3 diminishing with increase of pool size. The lack of a similar relationship between serum 25-(OH)D 3 and labelled 1,25-(OHhD3 in patients of the primary hyperparathyroidism group, with serum 25-(OH)D 3 less than 37 nmol/I (Table 2) , makes the latter alternative unlikely. So also do the observations on the formation of radioactive 24,25-(OH)2D 3. The mean serum concentration of non-radioactive 25-(OH)D 3 (65'5 nmol/l; so 30'5) in the subjects of group 1 who produced labelled 24,25-(OHhD3 was much greater than the mean value (14'75 nmol/I; so 5,75) in those producing labelled 1,25-(OHhD3 and this must imply corresponding differences in total body pools of 25-(OH)D3 . The concentration of labelled 24,25-(OH)2D3 at 48 h was correlated positively, albeit insignificantly, with both the serum 25-(OH)Dil (r = 0'3) and the serum labelled 25-(OH)D 3 (r = 0·48). Since both dihydroxylated metabolites are produced from the same precursor substrate, labelled 25-(OH)D 3, it is illogical to postulate that dilution of this radioactive precursor should limit the radioactive enrichment of 1,25-(OH)zD3 and at the same time apparently increase the enrichment of 24,25-(OH) 2D3. The most reasonable interpretation of the data is that, below a limiting concentration of 25-37'5 nmol/l, the formation of labelled I,25-(OHhD a is inversely related to the serum 25-(OH)D a (Fig. 4) ; above that limit, no I,25-(OHhDa is formed and labelled 24,25-(OHhD a is produced in proportion to the body pool of 24-(OH)D a (Fig. 5) . This interpretation is in general agreement with the results of animal experiments. In the rat, an administered pulse of 25-(OH)D a is metabolized to I,25-(OHhD a in vitamin D deficiency, and to 24,25-(OHhDa in animals replete with the vitamin (Galante, Colston, Evans, Byfield, Matthews & MacIntyre, 1973) . The effects of pre-existing body pools of vitamin D and its metabolites must inevitably complicate the interpretation of radioisotopic studies (Stanbury, Mawer, Hill, Holman, Jones & Van Den Berg, 1972) , but the results obtained in the present investigation suggest that this factor is outweighed by the physiological factors determining the formation of 1,25-(OHhDa.
The observation that the serum concentration of labelled I,25-(0H)2Da in subjects of group 1 was also significantly correlated with the serum calcium (Fig. 7) and the serum immunoreactive parathyroid hormone (Fig. 8) provides additional, indirect evidence that the regression in Fig. 4 represents a physiological relationship. A reduction of serum calcium and secondary increase of parathyroid secretion are expected consequences of vitamin D deficiency; and the state of vitamin D nutrition in the present study was assessed in the first place in terms of the serum concentration of 25-(0H)D a. In the thirteen subjects who produced labelled I,25-(OH)D a the serum 25-(OHhDa was 25 nmol/l or less. On the basis of these values, and the clinical state and nutritional history of these individuals (Table 1) , they can reasonably be regarded as having varying degrees of 'vitamin D deficiency'. The relationship shown in Fig. 4 suggests that the formation of! ,25-(OHhDafrom a single intravenous dose of cholecalciferol is regulated in proportion to the prevailing degree of physiological deficiency, more new metabolite being produced the greater the deficiency. If this interpretation is valid, the quantitative production of I,25-(0H)2Da from a standard dose of cholecalciferol might provide an objective means of defining and measuring 'vitamin D deficiency' in man. In these terms, the most reasonable explanation for the failure to detect labelled I,25-(OHhD a in the remaining seven subjects of group 1 (Table 1) is that none, or insignificant amounts, was formed; and that these subjects were individually physiologically replete with vitamin D, even although the measured serum 25-(OHhDa in one of them was 17·5 nmol/l. This accords with the clinical and nutritional state of these individuals (Table 1) .
The data obtained from the subjects of group 1 would be compatible with control of the formation of I,25-(OHhD a being mediated through change of serum calcium (Fig. 7) or serum immunoreactive parathyroid hormone (Fig. 8) , or by some other function of the state of vitamin D nutrition (Fig. 4) ; but it was not possible to identify any of these three interrelated variables as the primary determinant of the renal Ice-hydroxylation of 25-(0H)D a. Experiments in animals have been similarly inconclusive, different investigators attaching primary significance to each of these factors (Boyle, Gray & DeLuca, 1971; Fraser & Kodicek, 1973; Garabedian, Holick, DeLuca & Boyle, 1972; Larkins, MacAuley, Rapoport, Martin, Tulloch, Byfield, Matthews & MacIntyre, 1974; Rasmussen, Wong, Bikle & Goodman, 1972) . Primary hyperparathyroidism in man provides the potential for dissociating these normally interrelated factors. Individual patients were matched nutritionally with control subjects capable of producing labelled 1,25-(0H)2Da (Table 3) ; the serum calcium (mean 3·18 mmol/l; so 0'28) in each was above the concentration at which formation of this metabolite became undetectable in control subjects (Fig. 7) , and the adenomatous basis of the disease implies a reduced or absent reactivity of parathyroid hormone secretion to change in serum calcium (Lumb & Stanbury, 1974) . Since these patients produced the same amount of labelled I,25-(OH)2D a as their control subjects, despite the presence of hypercalcaemia (Fig. 7) , it is reasonable to exclude the serum calcium as determinant of its formation. These data conflict with the claim made for the rat that parathyroid hormone inhibits the formation of I,25-(0H) 2Da in the presence of hypercalcaemia (Galante, MacAuley, Colston & MacIntyre, 1972) . The lack of correlation between serum concentrations of labelled I,25-(OHhDa and of 25-(OH)D a in the primary hyperparathyroidism group suggests further that the formation of I,25-(0H) 2Da in primary hyperparathyroidism may be uninfluenced by the state of vitamin D nutrition (see Fig. 4 ). To establish this point unequivocally, it is necessary to extend observations to patients with serum 25-(OH)D a >37·5 nmolJ1 and such studies are in progress. With this reservation, it seems reasonable to attribute the continued formation of 1,25-(0H)2Da in hypercalcaemic primary hyperparathyroidism to the sustained inappropriate secretion of parathyroid hormone. By analogy, the effects of vitamin D deficiency in the subjects of group 1 might also be produced through accompanying changes of parathyroid function.
There was a highly significant proportional relationship between the serum concentration of labelled 1,25-(0H)2Da and serum immunoreactive parathyroid hormone in the subjects of group 1 (Fig. 8 ), but not in the patients with primary hyperparathyroidism (Fig. 9) . This difference may reflect a dose-response relationship or a saturation phenomenon. The serum immunoreactive parathyroid hormone exceeded 1 ng/ml in only two of the fifteen measurements available in subjects of group 1 (mean 0·44 ng/ml; so 0,53), whereas this value was exceeded in five of the eight patients with primary hyperparathyroidism ( Fig. 9 ; mean 1'74 ngjml; so 1'63). It is possible that maximum stimulation of 1ex-hydroxylation occurs with the moderate secondary hyperparathyroidism of vitamin D deficiency, and that no further effect is produced by the greater parathyroid activity in the particular group of patients with primary hyperparathyroidism studied.
On the basis of animal experiments, Tanaka & DeLuca (1973) have suggested that parathyroid hormone affects the renal synthesis of 1,25-(0H) 2Da indirectly, through its influence on serum PI or on the orthophosphate concentration of renal cells. In the present study there was no significant relationship between the serum concentration of labelled 1,25-(OHhDa and the serum Ph either in the primary hyperparathyroidism group (r = -0'18) or in the subjects of group 1 (r = -0'14). The mean serum PI in the primary hyperparathyroidism group (0'65 mmol/l; so 0,082) was significantly lower than in the control subjects producing labelled 1,25-(OHhDa (0'85 mmol{l; so 0'171; P<O·Ol). The reduced glomerular filtration in the patients with primary hyperparathyroidism would tend to limit the reduction of serum PI in response to parathyroid hormone, and it is conceivable that there was a greater reduction of renal cellular PI in these subjects than is suggested by the concentrations of serum PI. These patients produced the same mean serum concentration of labelled 1,25-(0H)2Da as their nutritionally matched control subjects (Table 3) , despite this evidence of secondary renal damage. It will be important to ascertain if the production of labelled 1,25-(OHhDa in cases of primary hyperparathyroidism with completely normal renal function is actually greater than in appropriately matched control subjects.
The significance of the derived molar concentrations of 1,25-(OHhDa in serum (Table 4) depends on the validity of the assumptions made. First, that the specific radioactivity of serum 25-(OH)D a does not change materially between 24 and 48 h after injecting the tracer; a limited number of observations indicates that this is the case (unpublished work). Secondly, that serum 1,25-(OHhD a is turning over sufficiently rapidly for the labelled 25-(OH)D a in the serum to be considered the exclusive source of the 1,25-(OHhDa measured at 48 h. There is no information available on the turnover of 1,25-(0H)2Da in man and this second assumption cannot be validated directly. In the chick, the half-life of injected 1,25-(0H) 2Da in serum is 4-5 h (Lawson & Emtage, 1974) ; in the rat it may be longer than this (Mawer, Backhouse, Hill & Taylor, 1975) , and both animal studies indicate that the 1,25-(OHhDa in the intestinal mucosa accounts for the greater part of the body pool, the amount in circulation being a relatively small fraction of the whole. The molar concentration of 1,25-(OHhDa in the serum, as estimated with these assumptions (Table 4) , showed only a fourfold variation in the vitamin D-deficient subjects of group 1, between the lowest value before (45 pmol/l) and the highest value after (185 pmol/l) injection of the labelled cholecalciferol. Because they produced no labelled 1,25-(OHhD a (Table 1) , it was not possible to estimate the concentration of this metabolite in the vitamin D-replete subjects of this group. With an independent biological assay used for 1,25-(0H)2Da (HilI, Taylor & Mawer, 1974) , its mean serum concentration in a separate group of vitamin D-replete subjects was 130 pmol{l (so 75), and comparable values have been obtained by competitive protein-binding assay (Brumbaugh, Haussler, Bressler & Haussler, 1974) . The close agreement between the results obtained by three very different techniques serves indirectly to validate the method of derivation used in the present study. The order of concentration and its small variation are compatible with the concept that 1,25-(OHhDa is produced in regulated quantity as a hormone, and the present investigation suggests that para-thyroid hormone functions as a trophic influence controlling its synthesis.
Because most of the subjects in group 1 were selected deliberately for their low vitamin D status, and since labelled 24,25-(OH) 2D 3 was detected only in those with serum 25-(OH)D 3 > 17,5-22'5 nmol/l (Table 1) , data on the formation of this metabolite are limited. Derivation of the molar serum concentration of 24,25-(OH)2D3 is also less secure than with 1,25-(OHhD3, as nothing is known either of its rate of turnover or of the dimensions of its body pool in any animal species. The concentrations calculated for the subjects of group 1 varied between 0·15 and 8'7 nmol/l, which, if valid estimates, would imply a higher range and greater variability than with the hormonal metabolite, 1,25-(OHhD 3. The relationship shown in Fig. 5 suggests that 24,25-(OHhD3 may be formed preferentially in vitamin D-replete subjects in proportion to the serum 25-(OH)D 3. No labelled 24,25-(OH)2D 3 was detectable in association with serum calcium <2·33 mmol/l (9'3 mg/lOO ml), serum PI < 0·97 mmol/l (3,0 mg/l00 ml) and serum [Cal x [Pl <2'26mmoP/F (28 mg 2/dP).
In the patients with primary hyperparathyroidism, the formation of labelled 24,25-(OHhD 3 was inappropriately high for the prevailing state of vitamin D nutrition ( Fig. 5; Table 3 ). Since the formation of labelled 1,25-(OHhD3 in these subjects was also inappropriately high for the prevailing serum calcium (Fig. 7) , primary hyperparathyroidism is associated with two apparent abnormalities of vitamin D metabolism. The simultaneous formation of significant amounts of the two renal metabolites of cholecalciferol (Table 2) implies that the turnover of 25-(OH)D 3 by the kidney in this disease is some two to three times greater than in nutritionally matched controls (Table 3) . If 24,25-(OH) 2D3 has no specific function, this would imply a net wastage of 25-(OH)D 3. But the combined renal metabolites represent so small a fraction of the administered dose that it is unlikely that such wastage could actually produce a conditioned deficiency of 25-(OH)D 3 or cholecalciferol in this disease.
